Company intelligence / Profile preview

NaDeNo Nanoscience

Trondheim, Trøndelag, Norwaynadeno.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

NaDeNo Nanoscience has developed a patented nanoparticle-based drug delivery system that encapsulates and protects FDA/EMA-approved cancer drugs, enabling direct, controlled release at tumor sites. Their lead candidate is a nanoformulation of cabazitaxel for intraperitoneal administration in peritoneal metastases. The technology aims to maximize local efficacy while minimizing systemic toxicity. Early preclinical results show improved tumor targeting and retention compared to traditional intravenous administration.[1]

Therapeutic areas: Oncology
Modalities: Small molecules (hydrophobic drugs)Nanoformulations (polymer nanoparticles)[1][2][5]
Industry: Biotech

Drug pipeline

1 asset

PACAB-002

Preclinical

Partnerships

AstraZeneca BioVentureHub[1]

Beyond the preview

Go deeper on NaDeNo Nanoscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NaDeNo Nanoscience.

Explore the full profile